| Target | Drug Name | RD Code | Approved(CN) | Company | Partner |
| EGFR-TKI (Gen 1) | Icotinib | 2011-06 | Betta | ||
| EGFR-TKI | Fruquintinib | 2018 | HutchMed | LO: Takeda | |
| EGFR-TKI (Gen 3) | Almonertinib | HS-10296 | 2020-03 | Hansoh | |
| EGFR-TKI (Gen 3) | Furmonertinib | AST2818 | 2021-03 | Allist | LO: ArriVent |
| EGFR-TKI | Sunvozertinib | 2023-08 | Dizal | ||
| EGFR-TKI | Befotertinib | D-0316 | 2023-05 | InventisBio <Betta> | |
| EGFR-TKI | Rezivertinib | BPI-7711 | 2024-05 | Beta | |
| EGFR-TKI | Rilertinib | SH-1028 | 2024-06 | Sanhome | |
| EGFR-TKI | Zorifertinib | 2024-11 | Alpha Bio | ||
| EGFR-TKI | Limertinib | ASK120067 | 2025-01 | Osaikang | |
| VEGFR | Apatinib | Hengrui | |||
| EGFR / HER2 / HER4 | Pyrotinib | Hengrui | |||
| BTK Inhibitor | Zanubrutinib | 2020-06 | BeOne | ||
| BTK Inhibitor | Orelabrutinib | ICP-022 | 2020-12 | InnoCare | |
| MET | Savolitinib | 2021-06 | |||
| MET | Vebreltinib | ||||
| Bcr-Abl TKI | Flumatinib | 2019-11 | Hansoh | ||
| Bcr-Abl TKI | Olverembatinib | HQP1351 | 2021-11 | Ascentage <Innovent> | LI:GIBH |
| PARP 1/2 | Pamiparib | 2021-05 | BeOne | ||
| PARP 1/2 | Fluzoparib | 2021 | Hengrui | ||
| HER2 | Neratinib | ||||
| PI3Kδ inhibitor | Linperlisib | 2022-11 | Yingli <Hengrui> | ||
| MEK | Tunlametinib | HL-085 | 2024-03 | KeChow | |
| Bcl-2 inhibitor | Lisaftoclax | APG-2575 | 2025-07 | Ascentage | |
| EZH2 | Zeprumetostat | SHR2554 | 2025-08 | Hengrui | LO: Treeline |
| ROS1 | |||||
| ALKi (Gen2 | Ensartinib | 2020-11 | Betta | Xcovery | |
| ALKi (Gen2 | Iruplinalkib | WX-0595 | 2023-03 | Qilu | |
| ALKi (Gen2 | Envonalkib | TQ-B3139 | 2024-06 | CTTQ | |
| ALKi (Gen2 | Dirozalkib | XZP-3621 | 2025-08 | Xuanzhu | |
| c-Met TKI | Gumarontinib | 2023-03 | Haihe | ||
| ROS1/ALK/c-Met | Unecritinib | TQ-B3101 | 2024-04 | CTTQ | |
| KRAS G12C | Fulzerasib | GFH925 | 2024-08 | GenFleet <Innovent> | |
| KRAS G12C | Garsorasib | D-1553 | 2024-11 | InventisBio <CTTQ> | |
| KRAS G12C | Glecirasib | JAB-21822 | 2025-05 | Jacobio <Allist> | |
| Multi Target | Donafenib | 2021-06 | Zelgen | ||
| Multi Target | Vorolanib | 2023-06 | Betta | ||
| CDK4/6 inhibitor | Dalpiciclib | 2021-12 | Hengrui | ||
| CDK4/6 | XZP-3287 | Xuanzhu | |||
| AR inhibitor | Rezvilutamide | 2022-06 | Hengrui |
China NMPA Approved New Drugs （Small Molecule）
